A randomized, double-blind, parallel-group study of Remibrutinib in Healthy Participants
Latest Information Update: 27 May 2025
At a glance
- Drugs Remibrutinib (Primary)
- Indications Chronic urticaria; Hidradenitis suppurativa; Multiple sclerosis; Myasthenia gravis; Peanut hypersensitivity
- Focus Therapeutic Use
Most Recent Events
- 27 May 2025 New trial record